Chronic Pain Management: Path to USD 10 Billion+ Opportunity

Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients to abuse them; increased recreational use of opioids has also been shown to lead to drug addiction. In a recent article, published in 2017, 11.5 million individuals were reported to have been caught misusing prescription opioids, while over 42,000 died from opioid overdose, in the US alone. The opioid crisis has prompted drug manufacturers to develop non-addictive, non-narcotic-based therapeutics / analgesics for chronic pain management.

The unmet need related to effective non-opioid narcotic therapies for the chronic pain management is evident across social media and various other online information portals.

With 8 approved drugs and over 140 clinical / preclinical candidates, the market for non-opioid chronic pain management solutions is growing at a commendable pace

As per Roots Analysis, the Non-Opioids for chronic pain management is fragmented across marketed, clinical and discovery pipeline. Further, it is worth highlighting that there are currently 8 drugs that are commercially available in market.

Companies with marketed drugs are also considering various life cycle management strategies in order to prolong the revenue generation potential of proprietary products.

Over time, several device-based pain management solutions have also emerged as viable alternatives to narcotic drugs / therapies.

Companies have raised over USD 1.5 billion in financing as investors have realized numerous benefits and future potential of non-opioid alternatives to chronic pain

Stakeholders are consistently demonstrating a heightened interest in investing in the non-opioids for chronic pain management market. It is noteworthy that over 50% of the funding has been secured through seed funding rounds.

In the last six years, over 70 partnership agreements were inked between various industry stakeholders; majority of these were focused on commercialization and acquisitions

Various Industry and Non-industry players are inked various deals where over 25% of the partnerships were focused on commercial agreements.

Prevalent trends indicate that the market is likely to grow at a significant pace as multiple late stage molecules receive marketing approval in the foreseen future.

The opportunity within the chronic pain treatment market is likely to be distributed across various drug classes targeting a diverse array of disease indications; late stage drug candidates are anticipated to sustain long term growth

The marker for non-opioids for chronic pain management is fragmented across various segments including drug class, indication and stage of development.

To learn more, please click Chronic Pain Treatment Market. For any queries / suggestions, please do not hesitate to contact us at You can also download the SAMPLE REPORT on chronic pain management by Roots Analysis.

Our Social Media Platform